Navigation Links
Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
Date:10/11/2010

MANHATTAN BEACH, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that President and CEO Robert Brooke will present a company overview during Precision IR's Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference.  The webcast presentation will be available Wednesday, October 13, at 1:00 p.m. Eastern time (10:00 a.m. Pacific time) by visiting the company's website at www.genesis-biopharma.com and an archive of the presentation will be available for 90 days.  

"We look forward to our presentation at the Informed Investors Conference as an opportunity to broaden our investment-community exposure during a pivotal period in our development," said Robert Brooke, President and CEO of Genesis Biopharma.  "Following the recent completion of a $700,000 financing, we are well positioned to advance development of our promising anti-CD55 antibody program."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential,, "suggests," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Announces $700K Private Financing
2. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
3. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
4. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
5. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
6. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
7. Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference
8. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
9. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
10. ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
11. ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):